Distribution of CMV serology and CMV reactivation at 1 year after HCT
| . | D/R serology . | Overall P value . | |||
|---|---|---|---|---|---|
| +/+ . | +/− . | −/+ . | −/− . | ||
| AML BM/PBSC, N (%) | 1816 (34) | 583 (11) | 1594 (30) | 1317 (25) | |
| CMV reactivation by 1 year | <.001 | ||||
| No | 1249 (69) | 511 (88) | 1085 (68) | 1256 (95) | |
| Yes | 565 (31) | 72 (12) | 507 (32) | 59 (4) | |
| Missing | 2 (<1) | 0 | 2 (<1) | 2 (<1) | |
| Days from TX to reactivation | 40 (1-355) | 46 (7-235) | 36 (2-337) | 44 (11-350) | .01 |
| ALL BM/PBSC, N (%) | 654 (35) | 246 (13) | 470 (25) | 513 (27) | |
| CMV reactivation by 1 y | <.001 | ||||
| No | 440 (67) | 231 (94) | 352 (75) | 490 (96) | |
| Yes | 210 (32) | 15 (6) | 118 (25) | 22 (4) | |
| Missing | 4 (<1) | 0 | 0 | 1 (<1) | |
| Days from TX to reactivation | 39 (4-359) | 47 (23-92) | 34 (2-329) | 41 (6-231) | .242 |
| CML BM/PBSC, N (%) | 436 (40) | 114 (11) | 211 (20) | 318 (29) | |
| CMV reactivation by 1 y | <.001 | ||||
| No | 296 (68) | 97 (85) | 126 (60) | 310 (97) | |
| Yes | 138 (32) | 16 (14) | 84 (40) | 7 (2) | |
| Missing | 2 (<1) | 1 (<1) | 1 (<1) | 1 (<1) | |
| No | 48 (1-264) | 57 (8-83) | 49 (4-330) | 53 (10-71) | .637 |
| MDS BM/PBSC, N (%) | 347 (29) | 131 (11) | 332 (28) | 387 (32) | |
| CMV reactivation by 1 y | <.001 | ||||
| No | 226 (65) | 119 (91) | 200 (60) | 376 (97) | |
| Yes | 119 (34) | 12 (9) | 132 (40) | 11 (3) | |
| Missing | 2 (<1) | 0 | 0 | 0 | |
| Days from TX to reactivation | 46 (1-322) | 43 (22-128) | 42 (1-362) | 70 (28-336) | .117 |
| . | D/R serology . | Overall P value . | |||
|---|---|---|---|---|---|
| +/+ . | +/− . | −/+ . | −/− . | ||
| AML BM/PBSC, N (%) | 1816 (34) | 583 (11) | 1594 (30) | 1317 (25) | |
| CMV reactivation by 1 year | <.001 | ||||
| No | 1249 (69) | 511 (88) | 1085 (68) | 1256 (95) | |
| Yes | 565 (31) | 72 (12) | 507 (32) | 59 (4) | |
| Missing | 2 (<1) | 0 | 2 (<1) | 2 (<1) | |
| Days from TX to reactivation | 40 (1-355) | 46 (7-235) | 36 (2-337) | 44 (11-350) | .01 |
| ALL BM/PBSC, N (%) | 654 (35) | 246 (13) | 470 (25) | 513 (27) | |
| CMV reactivation by 1 y | <.001 | ||||
| No | 440 (67) | 231 (94) | 352 (75) | 490 (96) | |
| Yes | 210 (32) | 15 (6) | 118 (25) | 22 (4) | |
| Missing | 4 (<1) | 0 | 0 | 1 (<1) | |
| Days from TX to reactivation | 39 (4-359) | 47 (23-92) | 34 (2-329) | 41 (6-231) | .242 |
| CML BM/PBSC, N (%) | 436 (40) | 114 (11) | 211 (20) | 318 (29) | |
| CMV reactivation by 1 y | <.001 | ||||
| No | 296 (68) | 97 (85) | 126 (60) | 310 (97) | |
| Yes | 138 (32) | 16 (14) | 84 (40) | 7 (2) | |
| Missing | 2 (<1) | 1 (<1) | 1 (<1) | 1 (<1) | |
| No | 48 (1-264) | 57 (8-83) | 49 (4-330) | 53 (10-71) | .637 |
| MDS BM/PBSC, N (%) | 347 (29) | 131 (11) | 332 (28) | 387 (32) | |
| CMV reactivation by 1 y | <.001 | ||||
| No | 226 (65) | 119 (91) | 200 (60) | 376 (97) | |
| Yes | 119 (34) | 12 (9) | 132 (40) | 11 (3) | |
| Missing | 2 (<1) | 0 | 0 | 0 | |
| Days from TX to reactivation | 46 (1-322) | 43 (22-128) | 42 (1-362) | 70 (28-336) | .117 |
Time from TX to reactivation expressed as mean (range). N, number of patients.